Paul Richardson

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement et al. · New England Journal of Medicine · 2021 · 853 citations · Full text

Public Health, Infectious Diseases, Pharmacotherapy +16

In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA

Nikhil Vergis, Stephen R. Atkinson, Suzanne Knapp et al. · Gastroenterology · 2016 · 189 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)

Craig W. Hendrix, Adriana Andrade, Namandjé N. Bumpus et al. · AIDS Research and Human Retroviruses · 2015 · 176 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn et al. · PLoS Medicine · 2018 · 172 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial

Hoosen Coovadia, Elizabeth R. Brown, Mary Glenn Fowler et al. · The Lancet · 2011 · 140 citations · Full text

Public Health, Child Health, Maternal Health +17